February 10, 2022

Detect Cancer Early & Increase Survival Rate Significantly | Mainz Biomed $MYNZ

Midas Letter
Midas Letter
Detect Cancer Early & Increase Survival Rate Significantly | Mainz Biomed $MYNZ
/

Sadly, we all know of someone who has suffered from cancer in one way or another. Either dealing with the disease themselves or witnessing it with a friend or family member. Early detection is the one thing we can universally say gives people the best chance of beating this killer disease. The development of cancer detection technology is something that can help increase survival rates significantly.

“Colon cancer is one of the main killers of cancer in the world. The second leading cancer death in the United States and it doesn’t have to be that way. That’s why we are doing what we are doing. Our test is scientifically designed in a way to pick up cancer at an earlier stage and then be able to eliminate late-stage cancer” – Mainz Biomed CEO Guido Baechler

Mainz Biomed (NASDAQ:MYNZ) develops molecular genetic diagnostic solutions for life-threatening conditions. Its flagship product, ColoAlert, is an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer. The kit which is sent to people’s homes uses stool samples to detect tumours better than the standard tests (FIT). Currently, the tests are available in Europe, and the company is in the middle of a US regulatory submission process intended to be launched in the first half of 2022.

A key business model differentiator between Mainz Biomed and the current testing standards is the company’s proposed partnerships with clinical labs. Today, detection kits are sent to one centralized lab in the US where results are measured. Mainz Biomed intends to provide kits to any and every lab in the world, where they will then distribute to people in need. This system is a much more efficient business model and should considerably speed test collection & results.

Mainz Biomed is also working on its next cancer detection product, PancAlert – an early-stage pancreatic cancer screening test. The detection system is based on real-time PCR detection of molecular-genetic biomarkers in stool samples. The potential for this style of test is to administer over 50 million tests per year in Europe alone. The product is supported by a federal grant from Germany’s Federal Ministry for Education and Research.

Mainz Biomed is also working on further tests for pre-cancer detection. Its goal is to develop tests that prevent cancer from happening in the first place using convenient sampling and genetic biomarkers.

Transcript

00:00 – Mainz Biomed $MYMZ CEO Guido Baechler
00:42 – Business overview
01:03 – Development stage of pipeline
01:23 – Total addressable market
02:07 – Detecting colorectal cancer earlier
03:59 – USA FDA approval
04:54 – Pancreatic Cancer detection product
05:10 – Business model differentiator
06:47 – Regulations
07:30 – Increase in survival rates
09:05 – Pre-cancer detection

Related Articles

Disclosure

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.